PPA
EGRX

Parametric Portfolio Associates’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Parametric Portfolio Associates’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$4.47M Buy
90,414
+23,397
+35% +$1.12M ﹤0.01% 1923
2021
Q4 		$3.41M Buy
67,017
+327
+0.5% +$16.9K ﹤0.01% 2113
2021
Q3 		$3.72M Buy
66,690
+17,545
+36% +$863K ﹤0.01% 2047
2021
Q2 		$2.1M Buy
49,145
+9,347
+23% +$386K ﹤0.01% 2406
2021
Q1 		$1.66M Buy
39,798
+2,402
+6% +$112K ﹤0.01% 2895
2020
Q4 		$1.74M Buy
37,396
+12,289
+49% +$575K ﹤0.01% 2754
2020
Q3 		$1.07M Buy
25,107
+165
+0.7% +$7.22K ﹤0.01% 2890
2020
Q2 		$1.2M Sell
24,942
-1,255
-5% -$62.6K ﹤0.01% 2818
2020
Q1 		$1.21M Sell
26,197
-5,426
-17% -$272K ﹤0.01% 2694
2019
Q4 		$1.9M Sell
31,623
-4,496
-12% -$268K ﹤0.01% 2723
2019
Q3 		$2.04M Sell
36,119
-4,975
-12% -$280K ﹤0.01% 2620
2019
Q2 		$2.29M Buy
41,094
+7,062
+21% +$368K ﹤0.01% 2581
2019
Q1 		$1.72M Buy
34,032
+14,925
+78% +$664K ﹤0.01% 2738
2018
Q4 		$770K Buy
19,107
+4,896
+34% +$252K ﹤0.01% 3122
2018
Q3 		$985K Buy
14,211
+1,965
+16% +$149K ﹤0.01% 3106
2018
Q2 		$927K Sell
12,246
-6,479
-35% -$408K ﹤0.01% 3095
2018
Q1 		$987K Sell
18,725
-1,018
-5% -$59.2K ﹤0.01% 3026
2017
Q4 		$1.05M Buy
19,743
+3,211
+19% +$179K ﹤0.01% 2995
2017
Q3 		$986K Buy
16,532
+9,017
+120% +$545K ﹤0.01% 3053
2017
Q2 		$593K Buy
7,515
+3,679
+96% +$301K ﹤0.01% 3264
2017
Q1 		$318K Sell
3,836
-12,799
-77% -$952K ﹤0.01% 3407
2016
Q4 		$1.32M Buy
16,635
+12,592
+311% +$915K ﹤0.01% 2662
2016
Q3 		$283K Buy
+4,043
New +$224K ﹤0.01% 3443
2016
Q1 		– Sell
-2,337
Closed -$207K – 4049
2015
Q4 		$207K Buy
+2,337
New +$185K ﹤0.01% 3724

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SGCIA
Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return

Parametric Portfolio Associates's EGRX Position: Q1 2022 in Review

Parametric Portfolio Associates increased its Eagle Pharmaceuticals, Inc. (EGRX) stake by 35% in Q1 2022, buying an estimated $1.12M and bringing the position to 90,414 shares worth $4.47M. The position accounts for ﹤0.01% of the portfolio, ranked #1923.

Parametric Portfolio Associates first reported a position in EGRX in Q4 2015 and has held it in 24 quarters since. 160 funds tracked by Wall St. Rank hold EGRX as of Q1 2022.

  • Parametric Portfolio Associates held 90,414 shares of Eagle Pharmaceuticals, Inc. worth $4.47M as of Q1 2022.
  • Parametric Portfolio Associates bought 23,397 Eagle Pharmaceuticals, Inc. shares in Q1 2022, an estimated $1.12M.
  • Eagle Pharmaceuticals, Inc. made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #1923 holding.
  • Parametric Portfolio Associates first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2015 and has held it in 24 quarters since.
  • 160 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.